Icatibant

CHEMBL2028850 Phase 4 Approuvé Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

1304.5 g/mol

LogP

-6.4

Phase

4

This synthetic peptide is used to treat acute attacks of hereditary angioedema (HAE) by blocking bradykinin B2 receptors. Bradykinin is the main mediator of the severe swelling episodes that characterize HAE, and blocking its receptor rapidly reduces swelling in the skin, abdomen, and airway. It is self-administered by subcutaneous injection at the first sign of an attack.

Masse moléculaire

1304,5000 g/mol

LogP

-6,40

TPSA

552,00 Å²

Règle des 5 de Lipinski

Non conforme

Aires thérapeutiques

Heart Failure

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

N=C(N)NCCC[C@@H](N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N1C[C@H](O)C[C@H]1C(=O)NCC(=O)N[C@@H](Cc1cccs1)C(=O)N[C@@H](CO)C(=O)N1Cc2ccccc2C[C@@H]1C(=O)N1[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)C[C@@H]2CCCC[C@@H]21

InChI

InChI=1S/C59H89N19O13S/c60-37(14-5-19-67-57(61)62)48(82)72-38(15-6-20-68-58(63)64)52(86)75-22-8-18-43(75)54(88)77-30-35(80)26-44(77)50(84)70-28-47(81)71-40(27-36-13-9-23-92-36)49(83)74-41(31-79)53(87)76-29-34-12-2-1-10-32(34)24-46(76)55(89)78-42-17-4-3-11-33(42)25-45(78)51(85)73-39(56(90)91)16-7-21-69-59(65)66/h1-2,9-10,12-13,23,33,35,37-46,79-80H,3-8,11,14-22,24-31,60H2,(H,70,84)(H,71,81)(H,72,82)(H,73,85)(H,74,83)(H,90,91)(H4,61,62,67)(H4,63,64,68)(H4,65,66,69)/t33-,35+,37+,38-,39-,40-,41-,42-,43-,44-,45-,46+/m0/s1

Molecular Formula

C59H89N19O13S

HBD / HBA

15 / 18

Liaisons Rotatives

30

Atomes Lourds

92

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

This synthetic peptide is used to treat acute attacks of hereditary angioedema (HAE) by blocking bradykinin B2 receptors. Bradykinin is the main mediator of the severe swelling episodes that characterize HAE, and blocking its receptor rapidly reduces swelling in the skin, abdomen, and airway. It is self-administered by subcutaneous injection at the first sign of an attack.

Yes, Icatibant is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2028850. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 6918173. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Icatibant sur PillFYI

Structure

Données Clés

Formule: C59H89N19O13S
Synonymes: 2

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.